Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly &Company, Indianapolis, Indiana, USA.
Lilly China Research and Development Center (LCRDC), Eli Lilly &Company, Shanghai, China.
Nat Med. 2017 Oct;23(10):1215-1219. doi: 10.1038/nm.4393. Epub 2017 Aug 28.
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-β (TGF-β) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism. A connection between GDF15 and body-weight regulation was initially suggested on the basis of an observation that increasing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer. In animal models, overexpression of GDF15 leads to a lean phenotype, hypophagia and other improvements in metabolic parameters, suggesting that recombinant GDF15 protein could potentially be used in the treatment of obesity and type 2 diabetes. However, the signaling and mechanism of action of GDF15 are poorly understood owing to the absence of a clearly identified cognate receptor. Here we report that GDNF-family receptor α-like (GFRAL), an orphan member of the GFR-α family, is a high-affinity receptor for GDF15. GFRAL binds to GDF15 in vitro and is required for the metabolic actions of GDF15 with respect to body weight and food intake in vivo in mice. Gfral mice were refractory to the effects of recombinant human GDF15 on body-weight, food-intake and glucose parameters. Blocking the interaction between GDF15 and GFRAL with a monoclonal antibody prevented the metabolic effects of GDF15 in rats. Gfral mRNA is highly expressed in the area postrema of mouse, rat and monkey, in accordance with previous reports implicating this region of the brain in the metabolic actions of GDF15 (refs. 4,5,6). Together, our data demonstrate that GFRAL is a receptor for GDF15 that mediates the metabolic effects of GDF15.
生长分化因子 15(GDF15),也称为 MIC-1,是转化生长因子-β(TGF-β)超家族的一个远亲成员,与各种生物学功能有关,包括癌症恶病质、肾和心力衰竭、动脉粥样硬化和代谢。最初,在观察到血清中 GDF15 水平的增加与晚期前列腺癌患者的体重减轻相关的基础上,提出了 GDF15 与体重调节之间的联系。在动物模型中,GDF15 的过表达导致瘦体型、食欲减退和代谢参数的其他改善,表明重组 GDF15 蛋白可能潜在地用于肥胖和 2 型糖尿病的治疗。然而,由于缺乏明确鉴定的同源受体,GDF15 的信号转导和作用机制仍不清楚。在这里,我们报告 GDNF 家族受体 α 样(GFRAL),GFR-α 家族的一个孤儿成员,是 GDF15 的高亲和力受体。GFRAL 在体外与 GDF15 结合,并且在体内 GDF15 对体重和食物摄入的代谢作用中是必需的。Gfral 小鼠对重组人 GDF15 对体重、食物摄入和葡萄糖参数的影响具有抗性。用单克隆抗体阻断 GDF15 和 GFRAL 之间的相互作用阻止了 GDF15 在大鼠中的代谢作用。Gfral mRNA 在小鼠、大鼠和猴子的后穹窿中高度表达,与先前报道一致,表明该脑区参与 GDF15 的代谢作用(参考文献 4、5、6)。总之,我们的数据表明 GFRAL 是 GDF15 的受体,介导 GDF15 的代谢作用。
Int J Obes (Lond). 2019-5-31
Trends Mol Med. 2017-11-9
Trends Endocrinol Metab. 2020-12
Trends Endocrinol Metab. 2018-6-1
J Cachexia Sarcopenia Muscle. 2025-8
Research (Wash D C). 2025-8-19
Int J Obes (Lond). 2014-12
Pharmacol Biochem Behav. 2013-9-21
Cytokine Growth Factor Rev. 2013-6-18
FEBS Lett. 2012-3-8
Endocrinol Metab Clin North Am. 2008-12